First Patient Dosed in Biomarker Study of Oral Alzheimer’s Therapy, ALZ-801

First Patient Dosed in Biomarker Study of Oral Alzheimer’s Therapy, ALZ-801
A first patient has been dosed in a Phase 2 trial evaluating the effects of ALZ-801 on disease-related biomarkers in people with early Alzheimer's disease, who have a specific genetic variant associated with an increased risk of disease progression. "This biomarker study is a key element of our overall Alzheimer’s clinical development program for ALZ‑801," Susan Abushakra, MD, chief medical officer of Alzheon, the company developing this possible therapy, said in a press release. ALZ-801 is an oral anti-oligomer agent — a medication that prevents the formation and clustering of harmful proteins, such as beta amyloid and tau, that play a key role in Alzheimer's. It has been given fast track status by the U.S. Food and Drug Administration (FDA) to support and speed its development. While there is no single cause of Alzheimer's, genetics are known to play a role in disease risk and progression. For instance, certain genetic variations in the apolipoprotein E gene (
Subscribe or to access all post and page content.